Navigation Links
Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
Date:9/25/2008

Results to be Presented at the North American Menopause Society 19th Annual

Meeting

EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr. Mary Tagliaferri, president and chief medical officer of Bionovo, will provide seminal information on the company's second estrogen receptor beta selective drug candidate that will be entering clinical trials shortly. Bionovo's drug candidate, VG101, is designed to treat postmenopausal vaginal dryness, a condition that affects over 40 million women.

The presentation will describe the mechanism of action of the company's selective estrogen receptor (ER) beta drug candidate and explain the safety advantages of this more highly selective estrogen receptor modulator, VG101, when compared to the currently available hormonal therapies for this indication. The presentation will detail the complete analysis of VG101 in both in vivo and in vitro models as well as present the clinical trial design for their upcoming Phase 1/2 study to evaluate the preliminary safety and efficacy of VG101 in a cohort of postmenopausal women. The presentation will include direct comparisons to existing estrogen therapies, showing VG101's superior efficacy at a cellular level.

"Vaginal dryness is a very painful, day to day, quality of life concern for over 50% of menopausal women. The only available FDA-approved treatment for women is estrogen, which has been proven to increase the risks for a number of potentially fatal dis
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...,, DETROIT, Nov. 6 Ca... CPD ) has launched ketorolac tromethamine ophtha...m the US Food and Drug Administration (FDA) for Su... for generic Acular® ophthalmic solution on t...ength of ketorolac is therapeutically equivalent t...
(Date:11/6/2009)...,, WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -...an informal working group of mid-market and smalle...sed concerns about H.R. 3962, the "Affordable Heal...crats last Thursday. These smaller companies fear...s in H.R. 3962 will hinder their efforts to bring ...
(Date:11/6/2009)...,, HOPKINTON, Mass., Nov. 6 Fac...uired all of the assets of Archus Orthopedics. The...tion in product offerings, intellectual property a...ation. "This is a win for patients suffering from ...resident & CEO, Geoff Pardo. "This consolidat...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962) 2Facet Solutions Acquires Archus Orthopedics 2Thoratec Corporation and HeartWare International Inc Announce Termination of Proposed Transaction 53378 1Thoratec Corporation and HeartWare International Inc Announce Termination of Proposed Transaction 53378 2Thoratec Corporation and HeartWare International Inc Announce Termination of Proposed Transaction 53378 3CandleInTheWindow org Announces 241000 Scholarship Prize Winners 53375 1CandleInTheWindow org Announces 241000 Scholarship Prize Winners 53375 2Genes key to staph disease severity drug resistance found hitchhiking together 53372 1Genes key to staph disease severity drug resistance found hitchhiking together 53372 2
...Clinical Trial for the Treatment of Pediatric Eosi...RN, Pa., Jan. 13 Cephalon, Inc . (Nasdaq: CEPH...d biopharmaceutical company, today announced that ...ephalon with an option to purchase all outstanding... option agreement, Cephalon will pay Ception a $10...
... of disease progression versus placebo , , - Sand...rowth for a median of 14 months compared to six mo... LAR as first treatment after surgery in certain p... (NETs) , , EAST HANOVER, N.J., Jan. 13 Sandosta...for injection) demonstrated antitumor benefit in p...
Other Medicine Technology:Cephalon Signs Option Agreement to Acquire Ception Therapeutics 2Cephalon Signs Option Agreement to Acquire Ception Therapeutics 3Cephalon Signs Option Agreement to Acquire Ception Therapeutics 4New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors 2New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors 3New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors 4New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors 5New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors 6
(Date:11/9/2009)...Natural Nutrition announced today the acquisition ...ly owned subsidiary of Natural Nutrition. Natural...p. and the company will focus its efforts on the b... developing mobile application market places throu...s focused on multi platform apps designed to run o...
(Date:11/9/2009)...SNewswire/ -- Today,s dramatic vote in the U.S. Ho...o meaningful health care reform. We are very pleas... makes health care more accessible and affordable ...romoting preventive care and improving delivery of...eminder of the tremendous amount of work we still ...
(Date:11/9/2009)... calls now available in New York City by pain mana...ork, NY (PRWEB) November 9, 2009 -- Davis Bregman...tine house calls to residents of Manhattan in New ...se call by calling the office at 212-918-1629 or ...enience of being able to see the doctor in the les...
(Date:11/9/2009)...e providing support and information to victims and...FaceofLungCancer.org. The site provides a communit...tant information and advocating change in health c...ember 9, 2009 -- With health care as the number on...f November’s designation as Lung Cancer Awar...
(Date:11/9/2009)...nector Corporation announces that their design, pr... Minneapolis, MN (Vocus) Nove...e leading manufacturer of miniature high-rel conne... QA systems have been certified to the ISO 9001:20...uality System Standard., , ,The company,s entire q...
Breaking Medicine News(10 mins):Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:The Face of Lung Cancer Support and Information Website Launches to Increase Awareness and Advocacy 2Health News:The Face of Lung Cancer Support and Information Website Launches to Increase Awareness and Advocacy 3Health News:Omnetics Connector Corporation Achieves AS9100 Certification 2
...Tony Abbott yesterday accused the commonwealth of ... over how the public money was spent.// He at...alised beggars" and blame-shifters who should be a...hort-changing public hospitals and favoring privat...
...ical Association has called for moratoriums on con...ical devices until it is shown that the products//...ical Association, U.S. largest physicians' group h...latory approval before direct-to-consumer advertis...
...gest producer of milk in the world but paradoxical...ldren being the worst deprived, parliament was inf...ty of milk in India is 229 gm per day as against 8...din told the Rajya Sabha that India produced over ...
...earchers mornings are the best time for one to und...rom the Duke University, in the US has analysed th...t their hospital, and have concluded that mornings...udy in the journal Quality and Safety in Healthcar...
...ceutical Union (IPU) has insisted that the 'mornin... counter to patients without a doctor's prescripti...ill, Levonelle, has been licensed for use in Irela...ble over the counter, as is the case in the UK. ...
...ing mix-up among about 135 people, whose blood wer... a re-test among 90 people as one of the patient's... in April. The pathology center has conceded...ithout knowing it. The mix-up was revealed w...
Other Medicine News:Health News:Health Minister Slams State Health Governments 2Health News:Drug Advertising needs to be Limited 2Health News:Surgeries Performed In The Morning Have Less Post-Op Complications 2Health News:The IPU Want Morning After Pills To Be Made Available Over The Counter 2
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: